Collaboration will enable rapid advancement of a joint preclinical proof of concept program for type 1 diabetes
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
New GMP facility for clinical and small-scale commercial pharmaceutical lipids
Dr. Adams brings more than two decades of experience leading the manufacturing of biologic and gene therapies at all stages of development.
This artificial RNA ligase has higher thermostability than natural RNA ligase
Fluor is providing architectural and engineering services and procuring equipment for the new 275,000 square-foot manufacturing facility that will house two manufacturing lines to double manufacturing capability
FDA also accepts a separate supplemental application to extend prophylaxis with PREVYMIS to 200 days in certain HSCT recipients
According to GlobalData’s analyst consensus forecast, OTX-2002 is projected to have the highest revenue by 2028, with sales of $1.6 billion during that year
Label expansion for CIBINQO provides new systemic oral option for adolescents (12 to <18 years) with moderate-to-severe atopic dermatitis
OmiCrisp has been developed with support from Centre for Cellular And Molecular Platforms C-CAMP-InDx Program
Subscribe To Our Newsletter & Stay Updated
